SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: paul ta who wrote (534)6/21/2001 10:42:50 AM
From: tom pope  Read Replies (2) | Respond to of 804
 
This is what Briefing says it says. Not pretty

>>10:34 ET Celgene (CELG) 27.25 -3.75: -- Update -- The NEJM (see 10:01 article) contains a letter to the editor in which Sloan Kettering and Mayo Clinic doctors note that a Celgene-supported trial of thalidomide therapy for multiple myeloma resulted in 4 of 15 patients experiencing deep venous thrombosis. Banc of America Securities says that the increased risk of thrombosis bears close watching.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News